Lyna Haybout

Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial

Santeri A. Pakola, Katriina Peltola, James H.A. Clubb et al. · Clinical Cancer Research · 2024 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial

Matthew S. Block, James H.A. Clubb, Johanna Mäenpää et al. · Nature Communications · 2025 · 29 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine

Saru Basnet, Mirte Van der Heijden, Dafne C.A. Quixabeira et al. · Molecular Therapy · 2024 · 19 citations · Full text

Life Sciences, Immunology, Oncology +17

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Elise Jirovec, Dafne C.A. Quixabeira, James H.A. Clubb et al. · Journal of Experimental & Clinical Cancer Research · 2024 · 18 citations · Full text

Medicine, Immunology, Oncology +17

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma

Tine Monberg, Santeri A. Pakola, Benedetta Albieri et al. · Cell Reports Medicine · 2025 · 15 citations · Full text

Life Sciences, Immunology, Oncology +17